Summary of In a Major Shift, Cancer Drugs Go ‘Tissue-Agnostic’

Looking for the article?
We have the summary! Get the key insights in just 5 minutes.

In a Major Shift, Cancer Drugs Go ‘Tissue-Agnostic’ summary

Editorial Rating



  • Innovative
  • Scientific
  • Hot Topic


Ken Garber reports on a breakthrough in the treatment of cancer. He explains so-called “tissue-agnostic” drugs in thorough detail, proving his longstanding experience as a science writer. He uses complex medical terms to discuss biomedical mechanisms and drug development. However, he manages to break down the essential information for a general audience. getAbstract recommends this article to anyone interested in new developments in cancer treatment.

About the Author

Ken Garber is a science writer in Ann Arbor, Michigan with longstanding experience covering biology and medicine. He has written for Science, Nature, Nature Biotechnology and Nature Medicine. He is also a contributing correspondent for the Journal of the National Cancer Institute.


What are tissue-agnostic drugs?

Until recently, doctors treated cancerous tumors with a drug regimen that was dependent on the type of tissue the tumor originated from (e.g. breast, prostate, lung or skin). Novel, “tissue-agnostic” drugs act on tumors independent of their tissue of origin. They can attack any solid tumor presenting a specific genetic marker.

Which tissue-agnostic drugs are available or in development?

The US Food and Drug Administration (FDA) had approved Merck’s pembrolizumab (Keytruda) to exclusively treat...

Comment on this summary

More on this topic

Immune System, Unleashed by Cancer Therapies, Can Attack Organs
Hacking the Code of Life
Making Sense of Coronavirus Mutations
Editing Humanity
Finding a New Purpose for Old Drugs
Researchers Race to Develop Antiviral Weapons to Fight the Pandemic Coronavirus

Related Channels